Morsa Images IDEAYA ( NASDAQ: IDYA ) reported positive interim Phase 1 expansion data for its drug candidate IDE397 in the treatment of MTAP-deletion urothelial and lung cancer. The data showed an overall response rate of approximately 33% in heavily pretreated patients with MTAP-deletion urothelial and.
Back to Health Page
